EGFR and non-small cell lung carcinoma: This study explores the urgent need for novel immunogenic treatments for advanced/metastatic mutant-EGFR/NSCLC patients, who currently receive the 3rd-generation TKI osimertinib as first-line treatment, and cannot receive ICI therapy for toxicity reasons, relying on standard chemotherapy beyond progression, without clear-cut stratification.